Application of Fuganlin oral liquid in preparation of anti-asthmatic and anti-inflammatory medicine for preventing and/or treating asthma

The technology of Fuganlin oral liquid and drug, which is applied in the field of drug application, can solve problems such as large influence on body tissues or organs, achieve inflammatory cell infiltration and improvement of perivascular edema, good clinical application and promotion value, inflammatory cell infiltration and vascular edema. Good effect on peripheral edema

Inactive Publication Date: 2021-02-26
GUANGZHOU YIPINHONG PHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The present invention aims at the problem that the current prevention and / or treatment of asthma has a great impact on body tissues or organs, and provides the application of Fuganlin oral liquid in the preparation and / or prevention or treatment of anti-inflammatory drugs for asthma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Fuganlin oral liquid in preparation of anti-asthmatic and anti-inflammatory medicine for preventing and/or treating asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Example 1: Experimental study on the influence of Fuganlin Oral Liquid on dust mite-induced young rat asthma model

[0017] 1. Test substance and reference substance

[0018] 1.1 Fuganlin Oral Liquid

[0019] 1.2 Xiaoer Dingchuan Oral Liquid

[0020] 1.3 Terbutaline Sulfate Tablets

[0021] 1.4 Negative control substance: pure water

[0022] 2. Experimental animal: SD rat

[0023] 3. Test materials

[0024] 3.1 Main reagents: PBS buffer solution (tablet), house dust mite allergen preparation, Dorminal 20%, His, IgEELISA kit.

[0025] 3.2 Main reagent preparation methods:

[0026] 3.2.1 PBS solution (take the configuration of 100mL as an example): take 1 tablet, add ultrapure water to 100mL, stir until completely dissolved, adjust the pH value to 7.2-7.6, sterilize under high pressure at 121°C for 30 minutes, cool for 2-8 ℃ refrigerator storage.

[0027] 3.2.2 ①1000SQ-U / mL house dust mite allergen preparation: 1000SQ-U / mL house dust mite allergen preparation solu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine application, and particularly discloses application of Fuganlin oral liquid in preparation of an anti-asthmatic and anti-inflammatory medicinefor preventing and / or treating asthma. The Fuganlin oral liquid provided by the invention has an obvious improvement effect on an immature rat asthma model induced by dust mites. Specifically, the Fuganlin oral liquid has inhibition effects on respiratory system resistance and respiratory system elasticity increase of dust mite-induced immature rats, and has an obvious inhibition effect on His content increase of dust mite-induced immature rats; and pathological examinations find that the Fuganlin oral liquid has good improvement effects on inflammatory cell infiltration and perivascular edemain lung tissues of dust mite-induced immature rats. Through pharmacodynamic tests and pathological examinations, the Fuganlin oral liquid can achieve symptomatic and supportive treatment and providereference for medicine new application clinical research, with good clinical application and popularization value.

Description

technical field [0001] The invention belongs to the technical field of drug application, and more specifically relates to the application of Fuganlin Oral Liquid in the preparation and / or prevention or treatment of asthma and anti-inflammatory drugs. Background technique [0002] Respiratory tract infection is the most common infectious disease in children, 90% of which are caused by viral infection, mainly in the nose and pharynx, and easily cause upper respiratory tract symptoms. Fuganlin Oral Liquid is used as a medicine for treating the above-mentioned upper respiratory tract infection, and is used to treat infantile colds and recurrent colds. As a pure Chinese medicine preparation, it has comprehensive effects such as antiviral and antipyretic. Chinese patent medicine is easy to popularize due to its advantages of "simple, convenient, cheap, and test", treating both symptoms and root causes, and less toxic and side effects. Whether it is used for health care or prevent...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/8966A61K9/08A61P11/00A61P31/12A61P11/06A61P11/14
CPCA61K9/0095A61K36/07A61K36/17A61K36/195A61K36/23A61K36/258A61K36/28A61K36/287A61K36/315A61K36/481A61K36/484A61K36/8966A61P11/00A61P11/06A61P11/14A61P31/12A61K2300/00
Inventor 李捍雄向飞军黄涌澜
Owner GUANGZHOU YIPINHONG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap